CN110139865A - Fgfr抑制剂 - Google Patents

Fgfr抑制剂 Download PDF

Info

Publication number
CN110139865A
CN110139865A CN201780081651.XA CN201780081651A CN110139865A CN 110139865 A CN110139865 A CN 110139865A CN 201780081651 A CN201780081651 A CN 201780081651A CN 110139865 A CN110139865 A CN 110139865A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acid
acceptable salt
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780081651.XA
Other languages
English (en)
Other versions
CN110139865B (zh
Inventor
张杨
王一恺
陈琳琳
冯韬
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN110139865A publication Critical patent/CN110139865A/zh
Application granted granted Critical
Publication of CN110139865B publication Critical patent/CN110139865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发公开了一类FGFR抑制剂，及其在制备治疗与FGFR相关疾病的药物中的应用。具体公开了式(I)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201780081651.XA 2016-12-29 2017-12-28 Fgfr抑制剂 Active CN110139865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016112541197 2016-12-29
CN201611254119 2016-12-29
PCT/CN2017/119285 WO2018121650A1 (zh) 2016-12-29 2017-12-28 Fgfr抑制剂

Publications (2)

Publication Number Publication Date
CN110139865A true CN110139865A (zh) 2019-08-16
CN110139865B CN110139865B (zh) 2022-02-18

Family

ID=62707918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780081651.XA Active CN110139865B (zh) 2016-12-29 2017-12-28 Fgfr抑制剂

Country Status (3)

Country Link
US (1) US11130761B2 (zh)
CN (1) CN110139865B (zh)
WO (1) WO2018121650A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057045A (zh) * 2020-06-05 2023-05-02 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂
CN109251179B (zh) * 2018-10-29 2021-04-13 郑州大学 1,2,4-三嗪类胃癌细胞生长抑制剂及其制备方法和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020236524A1 (en) * 2019-05-17 2020-11-26 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN114641293B (zh) * 2019-11-08 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 一种fgfr抑制剂的用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050019908A (ko) * 2002-07-19 2005-03-03 브리스톨-마이어스 스큅 컴퍼니 신규한 키나제 억제제
CN1681818A (zh) * 2002-07-19 2005-10-12 布里斯托尔-迈尔斯斯奎布公司 氮杂吲哚激酶抑制剂
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050019908A (ko) * 2002-07-19 2005-03-03 브리스톨-마이어스 스큅 컴퍼니 신규한 키나제 억제제
CN1681818A (zh) * 2002-07-19 2005-10-12 布里斯托尔-迈尔斯斯奎布公司 氮杂吲哚激酶抑制剂
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUN-HUI ZHANG ET AL.: "From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer", 《J.MED.CHEM.》 *
周文雅 等: "肉瘤中FGFR信号通路研究进展", 《中国骨与关节杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057045A (zh) * 2020-06-05 2023-05-02 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂

Also Published As

Publication number Publication date
US11130761B2 (en) 2021-09-28
CN110139865B (zh) 2022-02-18
US20210130357A1 (en) 2021-05-06
WO2018121650A1 (zh) 2018-07-05

Similar Documents

Publication Publication Date Title
CN110139865A (zh) Fgfr抑制剂
CN111247150B (zh) Fgfr抑制剂及其医药用途
TW210339B (zh)
CN104725362B (zh) 吡唑基喹喔啉激酶抑制剂
CN101326175B (zh) C-met/hgfr抑制剂的多晶型物
CN105358558B (zh) 作为tau‑pet‑配体的二氮杂咔唑衍生物
CN108026102A (zh) 可用于治疗与kit和pdgfr相关的病症的化合物
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
WO2018133829A1 (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
TW200526601A (en) Substituted acylpiperazine derivatives
EA019499B1 (ru) Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
CN109890820A (zh) 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
WO2019034075A1 (zh) Fgfr和egfr抑制剂
CN105593211A (zh) 吲哚和吲唑衍生物
WO2019154364A1 (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
WO2021115335A1 (zh) 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
CN110418790A (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
US20030114487A1 (en) Enantiomers of 6-[(4-chloro-phenyl)- hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1- methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
CN112979613B (zh) 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
CN107501270B (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN111499639A (zh) 嘧啶酮衍生物及其在制药中的应用
CN109952290A (zh) Fgfr4 抑制剂及其制备方法和应用
CN109890823A (zh) 稠合氮杂环化合物及其作为ampa受体调节剂的用途
TWI221473B (en) Process for the production of paroxetine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005464

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant